BioPharmSignal logoBioPharmSignal

Biotech News

Cardax Voluntarily Suspends SEC Reporting Obligations

Cardax Pharma (CDXI)Cardax PharmaSEC filing

CDXI (CDXI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is cdxi.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CDXICardax Pharma2023-12-06 20:00 EST

Cardax Announces Breakthrough Longevity Results with ZanthoSyn® in NIH-Funded Study

CDXICardax Pharma2021-08-31 22:18 EST

Cardax Refocuses on ZanthoSyn® Consumer Health Business

View all latest news

Cardax Pharma

Cardax was a specialty biopharmaceutical company focused on inflammation-related products and nutraceutical or therapeutic concepts. Its story was built around a narrow anti-inflammatory thesis.

Recent company news

CDXICardax Pharma2023-12-06 20:00 EST

Cardax Announces Breakthrough Longevity Results with ZanthoSyn® in NIH-Funded Study

CDXICardax Pharma2021-08-31 22:18 EST

Cardax Refocuses on ZanthoSyn® Consumer Health Business

CDXICardax Pharma2021-08-11 21:00 EST

Cardax Voluntarily Suspends SEC Reporting Obligations

CDXICardax Pharma2021-05-14 12:00 EST

Cardax Reports Q1 2021 Results

CDXICardax Pharma2021-04-15 12:00 EST

Cardax Reports 2020 Results

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States